• Profile
Close

A Phase 3, long-term, open-label safety study of galcanezumab in patients with migraine

BMC Neurology Nov 16, 2018

Camporeale A, et al. – In this phase 3, multicenter, randomized, long-term, open-label study, researchers assessed the safety, tolerability, and effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine. Study participants included patients (18 to 65 years of age) with episodic or chronic migraine who were not exposed previously to galcanezumab. Study participants were randomized to receive galcanezumab 120 mg or 240 mg, which was administered subcutaneously once monthly for a year. According to findings, 12 months of treatment with self-administered injections of galcanezumab was safe and related to a decline in the number of monthly migraine headache days. There were no significant differences in doses of galcanezumab in terms of safety and tolerability measures.

Full text available Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay